Test to determine if one or more variants are present in the CEBPA (CCAAT/enhancer binding protein alpha) gene of AML patients.
This provides prognostic information at diagnosis.
NOTE: CEBPA variants may also be detected on the Myeloid NGS Panel at a sensitivity of 5%. However, this panel may not call large insertion/deletion variants and coverage may not be optimal over the CEBPA gene. Please refer to the Myeloid NGS Panel in Test Manager for more details and price.
Genetics - Molecular Pathology
2x EDTA (Lavender) dedicated to Genetics (same sample can be used for FLT3/NPM1/CEBPA testing)
Send to MONC
8 ml peripheral blood in EDTA. 1-3 ml of bone marrow in EDTA or RPMI (anticoagulant).
Send ambient to the laboratory.
The CEBPA gene Is amplified by PCR and screened for insertion/deletion variants by fragment analysis. Sanger sequencing is only used to characterise variants detected by fragment analysis and screen for a second nucleotide substitution variant. CEBPA nucleotide substitution variants rarely occur on their own and will not be detected by the fragment analysis method.
$418.00 (Exclusive of GST)
"*" indicates required fields